Neervous investors slash 32% off QLT; Revenue warning send shares falling
Article Abstract:
Shares of QLT Inc. tumbled $20.05 (Canadian) on the Toronto stock Exchange to $41.95. The Vancouver-based pharmaceutical company had announced that sales of its photodynamic therapy, Visudyne would be between $36 million (U.S.) and $38 million instead of the anticipated $40 million.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
QLT weathers stormy selloff
Article Abstract:
After a shaky period in the market drug company QLT Inc. stabalizes and looks to a strong future as concerns over the reimbursment issues for its Visudyne drug are resolved.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
QLT profit jumps in third quarter
Article Abstract:
QLT Inc. turns third quarter profit. Company officials credits new eye drug with nearly tripling profits in the third quarter as Sun Life Financial takes in a small 6 percent profit, Canada Life Financial warns of losses.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Certicom, Entrust slash 30% of work forces, alter strategies. Zenastra aims to outgrow Ottawa's high-tech gorillas
- Abstracts: Cominco cashes in on demand for power with electricity sale. Cominco merger `logical,' Teck CEO says
- Abstracts: TIW (Telesystem International Wireless Inc.) to finance British unit. Telesystems beats IPO target in bid to prop up British unit